Cartesian Therapeutics, Inc.
RNAC
$10.76
-$0.495-4.40%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -98.10% | 31.91% | 49.64% | -62.40% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -98.10% | 31.91% | 49.64% | -62.40% | -- |
| Cost of Revenue | -16.11% | -48.15% | -63.15% | -74.99% | -- |
| Gross Profit | -206.01% | 143.11% | 137.12% | 71.39% | -- |
| SG&A Expenses | -24.78% | -23.52% | -15.03% | -5.90% | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.78% | -16.35% | -25.87% | -43.81% | -- |
| Operating Income | -122.31% | 34.58% | 52.26% | -34.55% | -- |
| Income Before Tax | 85.53% | 86.12% | 67.69% | -12,487.26% | -- |
| Income Tax Expenses | 101.51% | 101.51% | 101.51% | -3,019.87% | -- |
| Earnings from Continuing Operations | 84.21% | 84.97% | 64.76% | -16,364.63% | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.21% | 84.97% | 64.76% | -16,364.63% | -- |
| EBIT | -122.31% | 34.58% | 52.26% | -34.55% | -- |
| EBITDA | -120.47% | 36.93% | 53.28% | -39.63% | -- |
| EPS Basic | 96.89% | 97.17% | 78.16% | -520.29% | -- |
| Normalized Basic EPS | 92.83% | 97.07% | 91.12% | -317.30% | -- |
| EPS Diluted | 96.85% | 97.09% | 78.06% | -520.48% | -- |
| Normalized Diluted EPS | 92.87% | 96.97% | 91.02% | -317.79% | -- |
| Average Basic Shares Outstanding | 203.07% | 326.63% | 233.80% | 217.83% | -- |
| Average Diluted Shares Outstanding | 194.85% | 331.72% | 238.96% | 224.77% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |